A novel 90-amino acid cell-penetrating peptide (MTD4) that delivers plant defense activators and biostimulants directly into plant cells. When fused with the harpin protein HrpZ, MTD4-HrpZ significantly reduces bacterial disease infection and promotes growth in tomato plants, offering a sustainable protein-based alternative for organic crop protection.
This solution introduces a cell-penetrating peptide platform that enables the direct delivery of protein-based defense activators and biostimulants into plant cells. Built around the engineered 90-amino acid peptide MTD4, the platform addresses a long-standing challenge in agriculture: efficiently transporting bioactive proteins and peptides across the plant cell wall and membrane. When MTD4 is fused with the harpin protein HrpZ, the resulting MTD4-HrpZ construct activates plant immunity and stimulates growth, offering a sustainable, protein-based approach to crop protection that is well suited for organic agriculture systems.
In greenhouse validation trials, spraying tomato plants with 1 µM MTD4-HrpZ significantly reduced infection by bacterial speck and spot pathogens. A separate seedling treatment with 0.5 µM MTD4-HrpZ increased plant height and fresh weight by approximately 20%. These dual benefits—disease suppression and growth promotion—make the platform attractive for growers seeking to reduce reliance on synthetic agrochemicals while maintaining or improving yields.
Core technology:
Demonstrated performance:
The MTD4 delivery platform has been validated at the laboratory and controlled-environment level, with demonstrated efficacy in reducing bacterial disease and promoting growth in tomato. Current development objectives include optimizing the system for short peptide delivery, expanding efficacy testing in controlled environments, conducting field trials on tomato immunity and growth, and developing cost-effective production methods for large-scale agricultural deployment. The technology is positioned for transition from controlled-environment validation toward field-scale trials and commercial production scale-up.
The Ohio State University is a comprehensive public land‑grant research university in Columbus, serving one of the nation’s largest student populations and a broad research enterprise. Industry partners engage through an integrated academic medical center for clinical translation, a campus‑adjacent innovation district for co‑located projects, and a statewide extension network that pilots solutions across Ohio. Corporate engagement provides a single front door for sponsored research, talent pipelines, and streamlined agreements. Research is supported by competitive federal funding from agencies such as NIH, NSF, DOE, USDA, DoD, and NASA. A dedicated technology transfer office and venture support help protect IP, license technologies, and launch startups.